Cost-effectiveness analysis of ceftriaxone generic and patent in children with typhoid

Santi Purna Sari, Icut Diki Adestia Putri, Binar Nursanti

Research output: Contribution to journalArticlepeer-review


Objective: This study aimed to measure and compare the effectivity and cost of the two types of ceftriaxone to determine the more cost-effective treatment. Methods: In a cross-sectional analytical study, prescription and administrative financial data were retrospectively collected using the total sampling method. Data of 63 patients, comprising 43 and 20 patients treated with generic and patent ceftriaxone, respectively, were analyzed. The effectiveness of the treatment was measured in terms of the length of hospital stay of the patients. The total cost of the treatment was the total median of the costs of drugs, laboratory examinations, medical device usage, physician service, and hospitalization. Results: The effectiveness of both generic and patent ceftriaxone was 4 days of hospital stay. Cost-effectiveness ratio of generic ceftriaxone was Rp 575,937.25/day and that of patent ceftriaxone was Rp 888,601.75/day. Conclusion: Generic ceftriaxone was more cost-effective than patent ceftriaxone.

Original languageEnglish
Pages (from-to)76-80
Number of pages5
JournalInternational Journal of Applied Pharmaceutics
Issue numberSpecial Issue 1
Publication statusPublished - 1 Dec 2018


  • Ceftriaxone
  • Cost-effectiveness analysis
  • Karya bhakti Pratiwi Hospital
  • Pharmacoeconomic
  • Typhoid fever


Dive into the research topics of 'Cost-effectiveness analysis of ceftriaxone generic and patent in children with typhoid'. Together they form a unique fingerprint.

Cite this